Display options
Cite
Suzuki S, Shimazaki J, Morishita K, et al. Efficacy and safety of oxaliplatin, bevacizumab and oral S-1 for advanced recurrent colorectal cancer. Mol Clin Oncol. 2016;5(4):391-394doi: 10.3892/mco.2016.977.
Suzuki, S., Shimazaki, J., Morishita, K., Koike, N., Harada, N., Hayashi, T., & Suzuki, M. (2016). Efficacy and safety of oxaliplatin, bevacizumab and oral S-1 for advanced recurrent colorectal cancer. Molecular and clinical oncology, 5(4), 391-394. https://doi.org/10.3892/mco.2016.977
Suzuki, Shuji, et al. "Efficacy and safety of oxaliplatin, bevacizumab and oral S-1 for advanced recurrent colorectal cancer." Molecular and clinical oncology vol. 5,4 (2016): 391-394. doi: https://doi.org/10.3892/mco.2016.977
Suzuki S, Shimazaki J, Morishita K, Koike N, Harada N, Hayashi T, Suzuki M. Efficacy and safety of oxaliplatin, bevacizumab and oral S-1 for advanced recurrent colorectal cancer. Mol Clin Oncol. 2016 Oct;5(4):391-394. doi: 10.3892/mco.2016.977. Epub 2016 Aug 04. PMID: 27699032; PMCID: PMC5038216.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2016 Oct;5(4):391-394. doi: 10.3892/mco.2016.977. Epub 2016 Aug 04.

Efficacy and safety of oxaliplatin, bevacizumab and oral S-1 for advanced recurrent colorectal cancer.

Molecular and clinical oncology

Shuji Suzuki, Jiro Shimazaki, Keiichi Morishita, Nobusada Koike, Nobuhiko Harada, Tsuneo Hayashi, Mamoru Suzuki

Affiliations

  1. Department of Gastroenterological Surgery, Ibaraki Medical Center, Tokyo Medical University, Amimachi, Ibaraki 300-0395, Japan.
  2. Department of Surgery, Hachioji Digestive Disease Hospital, Hachioji, Tokyo 192-0903, Japan.

PMID: 27699032 PMCID: PMC5038216 DOI: 10.3892/mco.2016.977

Abstract

The aim of this study was to evaluate the efficacy and safety of co-administration of oral S-1 and oxaliplatin (SOX) in combination with bevacizumab (bev) in patients with advanced recurrent colorectal cancer. A retrospective study of 36 patients with advanced recurrent colorectal cancer was performed, of whom 27 received first-line and 9 received second-line SOX+bev chemotherapy between 2010 and 2013 at the Hachioji Digestive Disease Hospital (Hachioji, Japan). The SOX+bev regimen consisted of administration of intravenous oxaliplatin (85 mg/m

Keywords: S-1; SOX+bev; bevacizumab; colorectal cancer; oxaliplatin

References

  1. J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 - PubMed
  2. J Clin Oncol. 2000 Jan;18(1):136-47 - PubMed
  3. Lancet Oncol. 2010 Sep;11(9):853-60 - PubMed
  4. J Clin Oncol. 2010 May 20;28(15):2549-55 - PubMed
  5. Br J Cancer. 2000 Jul;83(2):141-5 - PubMed
  6. Lancet Oncol. 2012 Nov;13(11):1125-32 - PubMed
  7. Ann Oncol. 2009 May;20(5):892-6 - PubMed
  8. Cancer. 2004 Jun 1;100(11):2355-61 - PubMed
  9. Lancet Oncol. 2013 Dec;14(13):1278-86 - PubMed
  10. J Clin Oncol. 2004 Jan 15;22(2):229-37 - PubMed
  11. J Clin Oncol. 2006 Jan 20;24(3):394-400 - PubMed
  12. Br J Cancer. 2003 Mar 10;88(5):648-53 - PubMed
  13. Ann Oncol. 2004 Mar;15(3):460-6 - PubMed
  14. Br J Cancer. 2008 Mar 25;98(6):1034-8 - PubMed
  15. Jpn J Clin Oncol. 2009 Jan;39(1):2-15 - PubMed
  16. J Clin Oncol. 2004 Jan 1;22(1):23-30 - PubMed
  17. Anticancer Res. 2013 Sep;33(9):4029-32 - PubMed
  18. Lancet. 2000 Mar 25;355(9209):1041-7 - PubMed
  19. J Clin Oncol. 2004 Jun 1;22(11):2084-91 - PubMed
  20. N Engl J Med. 2005 Feb 3;352(5):476-87 - PubMed
  21. J Clin Oncol. 2000 Aug;18(16):2938-47 - PubMed

Publication Types